We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Blocking Fatty Acid Synthesis Kills Some Forms of Brain Cancer

By LabMedica International staff writers
Posted on 29 Dec 2009
A possible therapeutic approach to treat rapidly growing tumors is to inhibit the synthesis of the fatty acids they require for formation of new membranes and as an alternative energy source.

Investigators at the University of California, Los Angeles (USA) worked with the most common form of brain cancer, glioblastoma. More...
This is one of the most difficult to treat cancers with the median survival for patients of from only 12 to 18 months.

The investigators focused their attention on the master regulator of fatty acid synthesis, sterol regulatory element-binding protein 1 (SREBP-1), which is in turn controlled by signaling from the epidermal growth factor receptor (EGFR). Although nearly 50% of glioblastomas develop because of overexpressed or mutant EGFR, clinical trials testing EGFR inhibitors have not been particularly successful, with only about 10 to 15% of patients responding.

In the current study, the investigators used genetic and pharmacologic approaches to identify the signaling pathways that EGFR uses to activate SREBP-1. They reported in the December 15, 2009, issue of the journal Science Signaling that glioblastomas with overexpressed or mutant EGFR were more dependent on fatty acid synthesis than cancers lacking these characteristics. Breaking the link between EGFR and SREBP-1 in these tumors caused the cancer cells to self-destruct.

"This suggests an important link between cancer progression and fatty acid synthesis and has raised the idea that targeting fatty acid synthesis could be an effective way to block cancer growth," said senior author Dr. Paul Mischel, professor of pathology and laboratory medicine at the University of California, Los Angeles.

"We found that EGFR signaling does activate the master regulator SREBP-1 to increase the amount of fatty acids in the cells," said Dr. Mischel. "We also were able to uncover the molecular circuitry linking EGFR with increased fatty acid synthesis. This is exciting because it identified a previously undescribed EGFR-controlled metabolic pathway and suggests new treatment approaches for EGFR-activated glioblastomas and perhaps other cancers with amplified signaling. We hope that interrupting fatty acid synthesis will kill tumor cells and spare the normal cells, decreasing treatment side effects."

Related Links:
University of California, Los Angeles




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.